{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"trastuzumab-MCC-DM1"},{"type":"USBrandName","name":"Kadcyla"},{"type":"Synonym","name":"trastuzumab-DM1"},{"type":"Abbreviation","name":"T-DM1"},{"type":"Synonym","name":"trastuzumab-MCC-DM1 antibody-drug conjugate"},{"type":"CodeName","name":"PRO132365"},{"type":"Synonym","name":"trastuzumab emtansine"},{"type":"Synonym","name":"trastuzumab-MCC-DM1 immunoconjugate"},{"type":"CodeName","name":"RO5304020"},{"type":"CASRegistryName","name":"1018448-65-1"},{"type":"Synonym","name":"ado trastuzumab emtansine"},{"type":"ChemicalStructureName","name":"immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal RhuMab HER2 gamma1-chain), disulfide with human-mouse monoclonal RhuMab HER2 light chain, dimer, tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine"}],"definition":{"html":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","text":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/ado-trastuzumab-emtansine","text":"Ado-Trastuzumab Emtansine"},"nciConceptId":"C82492","nciConceptName":"Trastuzumab Emtansine","termId":564399,"name":"ado-trastuzumab emtansine","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"trastuzumab-emtansine"}],"links":null}